×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Therapeutic: Lipid Raft Modulation for Parkinson's Disease (MLSM Hypothes
therapeutic
1,332 words
KG: Lipid Raft Modulation for Parkinson's Disease (MLSM Hypothesis)
2026-03-22
kind:therapeutic
section:therapeutics
state:published
Contents
Lipid Raft Modulation for Parkinson's Disease (MLSM Hypothesis)
💊
Therapeutic Info
Name
Lipid Raft Modulation for Parkinson's Disease (MLSM Hypothesis)
Summary
Experimental protocol for testing the Membrane-Lipid-Synuclein-Mitochondria hypothesis using lipid raft modulators in PD patient-derived neurons
Knowledge Graph
Related Hypotheses (30)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Flotillin-1 Stabilization Compounds
Score: 0.42
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.65
Circadian Glymphatic Entrainment via Targeted Orexin Recepto
Score: 0.62
Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu
Score: 0.57
Senescence-Induced Lipid Peroxidation Spreading
Score: 0.53
Vagal Afferent Microbial Signal Modulation
Score: 0.52
Senescence-Associated Myelin Lipid Remodeling
Score: 0.51
Astroglial Gap Junction Coordination via Connexin-43 Phospho
Score: 0.50
Lysosomal Calcium Channel Modulation Therapy
Score: 0.49
Orexin-Microglia Modulation Therapy
Score: 0.49
Gut Barrier Permeability-α-Synuclein Axis Modulation
Score: 0.49
RNA Granule Nucleation Site Modulation
Score: 0.48
Metabolic Circuit Breaker via Lipid Droplet Modulation
Score: 0.48
Sphingomyelin Synthase Activators for Raft Remodeling
Score: 0.47
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46
Hypocretin-Neurogenesis Coupling Therapy
Score: 0.45
Astrocytic Connexin-43 Upregulation Enhances Neuroprotective
Score: 0.45
Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modu
Score: 0.44
Lysosomal Positioning Dynamics Modulation
Score: 0.43
Extracellular Matrix Stiffness Modulation
Score: 0.43
Serine/Arginine-Rich Protein Kinase Modulation
Score: 0.42
CX43 hemichannel engineering enables size-selective mitochon
Score: 0.41
Mitochondrial Calcium Buffering Enhancement via MCU Modulati
Score: 0.38
Extracellular Vesicle Biogenesis Modulation
Score: 0.34
Trans-Synaptic Adhesion Molecule Modulation
Score: 0.34
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49
APOE-Mediated Synaptic Lipid Raft Stabilization
Score: 0.43
Show 25 more
Related Analyses (26)
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Show 21 more
Related Experiments (30)
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.46
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.46
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.46
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.46
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.46
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.46
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.46
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.46
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.46
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.46
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.46
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.46
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.46
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.46
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.46
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.46
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.46
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.46
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.46
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.46
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.46
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.46
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.46
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.46
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.46
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.46
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.46
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.46
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.46
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.46
Show 25 more